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ABSTRACT
The RFX DNA binding domain (DBD) is a novel highly
conserved motif belonging to a large number of
dimeric DNA binding proteins which have diverse
regulatory functions in eukaryotic organisms, ranging
from yeasts to human. To characterize this novel motif,
solid phase synthesis of a 76mer polypeptide
corresponding to the DBD of human hRFX1 (hRFX1/
DBD), a prototypical member of the RFX family, has
been optimized to yield large quantities (∼90 mg) of
pure compound. Preliminary two-dimensional 1H NMR
experiments suggested the presence of helical regions
in this sequence in agreement with previously reported
secondary structure predictions. In gel mobility shift
assays, this synthetic peptide was shown to bind in a
cooperative manner the 23mer duplex oligo-
deoxynucleotide corresponding to the binding site of
hRFX1, with a 2:1 stoichoimetry due to an inverse repeat
present in the 23mer. The stoichiometry of this complex
was reduced to 1:1 by decreasing the length of the DNA
sequence to a 13mer oligonucleotide containing a single
half-site. Surface plasmon resonance measurements
were achieved using this 5′-biotylinated 13mer oligo-
nucleotide immobilized on an avidin-coated sensor
chip. Using this method an association constant (Ka =
4 × 105/M/s), a dissociation constant (Kd = 6 × 10–2/s) and
an equilibrium dissociation constant (KD = 153 nM)
were determined for binding of hRFX1/DBD to the
double-stranded 13mer oligonucleotide. In the presence
of hRFX1/DBD the melting temperature of the 13mer
DNA was increased by 16C, illustrating stabilization
of the double-stranded conformation induced by the
peptide.
INTRODUCTION
The RFX family of proteins consists of highly homologous
site-specific DNA binding proteins designated RFX1–5 in man
and mouse (1,2) Sak1 in Shizosaccharomyces pombe (3), ScRFX
in Saccharomyces cerevisiae and CeRFX in Caenorhabditis
elegans (4). These proteins are characterized by several highly
conserved sequences, among which the most prominent is a novel
76 amino acid DNA binding domain (DBD) designated the RFX
DNA binding motif (1,2). The recent identification of several
new RFX genes has permitted a precise definition of the
consensus motif present in the DBD and has shed light on the
evolutionary conservation and functional importance of RFX
proteins (4). These proteins function as regulatory factors in a
wide variety of unrelated systems, including regulation of the
mitotic cell cycle in yeast fission, control of the immune response
in mammals and promotion of infection by human hepatitis B
virus. Thus RFX1 was shown to be a cellular transactivator used
by the highly pathogenic hepatitis B virus (5,6), while RFX5, a
75 kDa subunit of a nuclear protein complex, is involved in
transcription of MHC class II, Ii chain and DM genes (7–9).
These genes play a key role in the immune system by controlling
presentation of foreign antigenic peptides to CD4+ helper T
lymphocytes. The RFX family of proteins appears, therefore, as
widespread and functionally important group of proteins as those
containing other well-known DNA binding motifs, such as the
well-known zinc finger, homeodomain, basic leucine zipper and
basic helix–loop–helix proteins.
The DNA binding motif shared by RFX1–5, Sak1, ScRFX and
CeRFX proteins has no significant homology with any other
known DNA binding motif (4; Fig. 1A). It is characterized by 30
highly conserved amino acids clustered in the C-terminal half of
the domain. Particularly prominent are four glycine residues and
numerous aromatic (W, F and Y), basic (K and R) and
hydrophobic (I, L and V) residues.
The human hRFX1 protein binds DNA as homodimeric or
heterodimeric (RFX1/RFX2 and RFX1/RFX3) complexes
whose specific binding sites are inverted repeats, referred to as
either EF-C or MDBP, or MHC class II X box motifs (Fig. 1B).
These motifs are present in several cellular genes as well as in the
enhancers of polyomavirus, cytomegalovirus and hepatitis B
virus (2,5). The domain responsible for dimerization of hRFX1
corresponds to a conserved region situated in the C-terminal part
of the protein, 220 amino acids downstream of the DBD.
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Figure 1. (A) Alignment between the DBD sequences of all known human RFX proteins. Amino acids that are identical or similar are boxed. The secondary structure
prediction (20) is indicated below the sequences. Positions of the predicted α-helices and β-strand (extended) are indicated by boxes. (B) 23 bp DNA duplex containing
the EF-C/MDBP target site of hRFX1/DBD. The presence of an inverted repeat in the sequence allows hRFX1 to bind as a homodimer (left). In order to simplify this
model, our aim in this study was to obtain a 1:1 stoichiometric complex between the DBD of hRFX1 and one half-site of the EF-C/MDBP target site (right).
In order to characterize more precisely the mode of DNA
recognition by proteins of the RFX family, the DBD of hRFX1
(hRFX1/DBD) was chosen as a model. Synthesis of this domain
(76 amino acids) was achieved by the solid phase method, which
required optimization of several coupling steps. The resulting
peptide was obtained in large quantities (90 mg), allowing us to
perform preliminary 600 MHz 2D 1H NMR experiments,
suggesting the occurrence of helical regions in the sequence. The
synthetic peptide was also used to determine the minimum DNA
binding site in order to simplify study of the interaction of
hRFX1/DBD with DNA. The biotinylated 13mer DNA duplex
characterized in this preliminary study was then immobilized on
a streptavidin-coated biosensor chip in order to determine its
kinetic binding parameters with hRFX1/DBD by surface plasmon
resonance analysis and its selectivity for a double-stranded DNA.
Finally, DNA duplex denaturation experiments were undertaken
in order to investigate the effect of hRFX1/DBD on duplex stability.
MATERIALS AND METHODS
Peptide synthesis
Wang resin, piperidine, N-methylpyrrolidone, dichloromethane,
dimethylaminopyridine, dicyclohexylcarbodiimide and 1-hydroxy-
benzotriazole were purchased from Perkin-Elmer (Saint Quentin
en Yvelines, France). Trifluoroacetic acid was from SDS (Peypin,
France) and triisopropylsilane and phenol were from Aldrich
(Strasbourg, France).
Assembly of the protected peptide chain was carried out using
the stepwise solid phase method of Merrifield (10) on an Applied
Biosystems 431A automated peptide synthesizer. The different
syntheses were run at 40 µmol scale on Wang resin (loading
1 mmol/g dry resin). Fmoc-protected amino acids were used with
the following sidechain protection groups: t-butyl ether (Ser, Thr
and Tyr); t-butyl ester (Glu and Asp); trityl (Cys, His, Asn and
Gln); 2,2,5,7,8-pentamethylchroman-6-sulfonyl-5-(Arg), t-butoxy-
carbonyl (Lys and Trp). The hydroxy function on Wang resin was
esterified by Fmoc alanine-activated as a symetrical anhydride
with dimethylaminopyridine as the acylation catalyst. Deprotection
of the Fmoc group during complete synthesis was obtained by
three successive 3 min treatments with 20% piperidine in
N-methylpyrrolidone. Successive couplings were performed with
dicyclohexylcarbodiimide/hydroxybenzotriazole in N-methyl-
pyrrolidone as coupling agent. Single couplings of 45 min were
used (total cycle 1 h 15 min). N,O-bisFmoc derivatives of
N-(2-hydroxy-4-methoxybenzyl)glycine was used for coupling
of Gly53 in the second synthesis and for coupling of Gly44 and
Gly53 in the third synthesis. In both cases coupling of the amino
acid immediately following these glycines was performed using
the symetric anhydride procedure with dicyclohexylcarbodiimide in
dichloromethane as described in Johnson et al. (11). Fmoc
deprotection in these syntheses was followed by spectrophotometric
monitoring of the dibenzofulvene piperidine adduct at λ = 301 nm
(Fig. 2). The total time to carry out complete synthesis was 102 h
(4 days) in the optimized synthesis (Fig. 2C). The peptide resins
were treated for 4 h with 40 ml trifluoroacetic acid containing
phenol (3 g), H2O (2 ml) and triisopropylsilane (1 ml) in order to
cleave the peptide from the resin and to remove the protecting
groups from the amino acid sidechains. Trifluoroacetic acid was
removed under vacuum and the peptide precipitated with
t-butylmethyl ether previously cooled to –20C. Fractions of 384,
235 and 705 mg crude peptide were obtained in the first, second
and third syntheses respectively (Fig. 2). Purification of the
peptide was carried out by reverse phase HPLC on a Vydac C4
10 × 250 mm column with a linear gradient of 20–70% B over
90 min (A, 0.1% trifluoroacetic acid in H2O; B, 70% acetonitrile,
0.09% trifluoroacetic acid in H2O) at a flow rate of 2 ml/min with
detection at a wavelength of 234 nm. The fractions containing the
pure peptide (∼60 min retention time) were collected and freeze
dried to afford 28, 12 and 88 mg purified HRFX1 in the first,
second and third syntheses, corresponding to 7, 3 and 21% yield
respectively (mol. wt 10 531 as the trifluoroacetate salt). The
quality of each synthesis was determined using HPLC and
electrospray mass spectrometry (Fig. 3).
NMR experiments
hRFX1/DBD was dissolved in water containing 30% TFE-d2
(SDS, Peypin, France) to a final sample concentration of 1 mM.
Two-dimensional phase-sensitive 1H Clean-TOCSY (70 ms spin
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Figure 2. Ultraviolet monitoring (λ301 nm) of Fmoc deprotection during the
three different syntheses of the DBD of hRFX1. The scheme is limited to the
38–55 region of hRFX1/DBD because the difficult couplings and deprotections
were located only in this part of the synthesis. The sequence 38–55 of hRFX1
is represented in the reverse orientation, which corresponds to the order of
incorporation of solid phase synthesis from the C- to the N-terminus. (A) Fmoc
deprotection scheme of the first synthesis. Difficult couplings and deprotections are
located from Ser49 to Gly44. (B) Incorporation of a 2-hydroxy-4-methoxy-benzyl
as amino protecting group of Gly53 prevented any synthesis problem until
Gly44, but new synthetic difficulties occurred at Phe43–Ala40. (C) The use of
2-hydroxy-4-methoxy-benzyl groups at Gly53 and Gly44 definitively solved
the synthesis problems. The double intensity of peak heights corresponding to
deprotection of Gly53, Met52, Gly44 and Phe43 is due to the presence of a
N,O-bisFmoc on the glycine derivative, and the subsequent N,O double
coupling of Fmoc methionine and Fmoc phenylalanine is due to the activation
procedure of these residues as symmetrical anhydrides.
lock) (12) and NOESY (mixing times 100 and 200 ms) (13)
spectra utilizing time-proportional phase incrementation (14)
were recorded at 293 K and pH 4.0.
NMR spectra were recorded on a Brüker AMX 600 spectrometer
operating at 600.14 MHz without sample spinning with 2K real
t2 points, with a spectral width of 7246 Hz, and 512 t1 increments.
The transmitter frequency was set to the water signal, which was
suppressed by irradiation during the relaxation delay of 1.6 s
between scans, and a water gate sequence before acquisition. The
temperature was externally controlled using a SK107 unit (Haake
GmbH, Karlsruhe, Germany). The data were processed with
FELIX (Biosym/MSI). Phase-shifted sine bell (shifted by pi/6)
window functions were applied prior to Fourier transformation in
both dimensions. The 1H chemical shifts were referenced to
hexamethyldisilazane (HMDS; SDS, France), used as internal
standard.
Figure 3. HPLC chromatograms of the crude (A) and purified (B) products
from the third synthesis of hRFX1/DBD. The analyses were obtained with an
acetonitrile gradient of from 50 to 80% B over 15 min at a flow rate of 1 ml/min
on a capcell C8 column (5 µm, 300 Å, 250 × 4.6 mm) with UV detection at λ
= 214 nm; A, 0.1% TFA in H2O; B, 70% CH3CN, 0.09% TFA in H2O. The
retention time of the purified hRFX1 is 9.7 min under these conditions.
(C) Ionisation electrospray mass spectrum of the purified hRFX1/DBD.
Gel mobility shift assays
Binding conditions and gel electrophoresis were carried out
essentially as described (2,5). Briefly, 100 000 c.p.m. (50 pg)
double-stranded oligonucleotide probes (end-labeled with 32P)
were diluted with known amounts (see figure legends) of
unlabeled oligonucleotide and incubated for 30 min on ice with
10 ng hRFX1/DBD in 20 µl binding buffer. Binding buffer was
as described (2,5). Sequences of the duplex oligonucleotides were
as follows: 23mer, 5′-GGCCAGTTGCCTAGCAACTAATT-3′;
16mer, 5′-CCCCTAGCAACAGATG-3′; 13mer, 5′-CCCCTAG-
CAACAG-3′; 12mer, 5′-CCCTAGCAACAG-3′. Only the upper
strand is shown. Half-sites are underlined.
Surface plasmon resonance experiments
The BIAcore system used in these studies is from Pharmacia
Biosensor AB (Uppsala, Sweden). Sensor chips and surfactant
P20 were from Pharmacia Biosensor AB. N-Hydroxysuccinimide
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(NHS), N-ethyl-N′-(3-diethylaminopropyl)carbodiimide (EDC),
diaminopropane and streptavidin were purchased from Sigma.
The complementary 13mers 5′-CCCCTAGCAACAG-3 and
5′-CTGTTGCTAGGGG-3′, biotinylated or not, were from
Birsner & Grob-Biotech GmbH (Denzlingen, Germany).
The surface of the CM5 sensor chip was derivatized with
streptavidin (2300 RU) using the EDC-NHS procedure according to
the manufacturer’s recommendations, followed by inactivation of
the uncoupled dextran carboxylic groups with 1 M diaminopropane
in H2O.
Hybridization of 2.5 µg 13mer 5′-biotin(5′-CTGTTGCTAGG-
GG-3′) was performed using 3.75 µg complementary 13mer
(5′-CCCCTAGCAACAG-3′) in 500 µl 50 mM HEPES, pH 7.4,
0.5 M NaCl, 5 mM MgCl2. After 1 h at 60C, the temperature was
allowed to decrease overnight to room temperature. Three
different amounts of double-strand biotinylated oligonucleotide
were immobilized on the sensor chip using 20 µl stock solution
diluted 1:10 with prehybridized DNA which were injected at a
flow rate of 5 µl/min over the three channels of the sensor chip.
This led to immobilization of 120, 140 and 170 RU respectively.
Binding experiments were carried out at 25C in 10 mM
HEPES, pH 7.4, 0.15 M NaCl, 10 mM MgCl2, 0.3 mM DTT,
3 mM EDTA, 0.005% P20. For kinetic studies 40 µl solutions of
HRFX1 at concentrations ranging from 50 to 800 nM were
injected at 20 µl/min. Concentration and ratio between peptide and
immobilized nucleic acids were determined using the equation:
n = (RUpeptide/RUDNA) × (MWDNA/MWpeptide) 1
in which n is the stoichiometry of the complex, RU is the
resonance unit and MW is the molecular weight.
After each injection of protein over the DNA, the sensor chip
surface was regenerated by a 5 µl pulse (15 s) of 1 M NaCl in
binding buffer.
Determination of kinetic constants
Apparent kinetic rates were calculated using the BIAcore 2.0
analytical software. To fit the dissociation curves, a single
exponential dissociation rate equation
y Re–Kdt 2
was used, where R is the observed response at the beginning of
dissociation and Kd is the dissociation rate constant.
For determination of the association rate constant Ka, the
binding curve of the sensorgram was fitted to the exponential
function
R Req(1 – e–Ks(t – tO)) 3
where
Ks = KaC + Kd 4
C is the molar concentration of injected protein, Ka is the apparent
association rate constant in per M/s units. Ks was plotted against
concentration and the slope of the curve provided the apparent Ka
value.
DNA duplex melting temperature
DNA denaturation experiments were achieved with a UVIKON
941 UV spectrophotometer piloted by KONTRON acquisition
software for melting temperatures. Aliquots of 1.5 ml of a 1.5 µM
solution of the 13mer oligodeoxynucleotide 5′-CCCCTAG-
CAACAG-3′/5′-CTGTTGCTAGGGG-3′ solution and 2 µM
hRFX1/DBD in 10 mM HEPES, pH 7.4, 1 mM β-mercaptoetha-
nol were heated over a gradient of temperature ranging from 4 to
65C at 20C/h. Two other cells containing the same concentra-
tion of oligodeoxynucleotide or hRFX1/DBD respectively were
used as controls. The absorbance at λ260 nm, which corresponds
to maximum absorbance of nucleotide bases, was expressed in
relative units and recorded. The absorbance of hRFX1/DBD
alone at the same concentration (Do ∼ 0.01 RU) was recorded and




Solid phase synthesis of the DBD of hRFX1 was carried out in a
stepwise manner on Wang resin using the Fmoc/tBu strategy (15).
Figure 2 shows UV monitoring of Fmoc deprotection during the
different syntheses of hRFX1. The comparison of relative peak
height at each deprotection step allows quantification of the
amount of deprotection of the temporary protecting group Fmoc
and consequently allows an estimation of the efficiency of the
previous coupling. In Figure 2A, the Fmoc deprotection signal
decreases from Ser49 to Gly44, indicating that incomplete
coupling and deprotection are obtained under such conditions.
This special feature is known as a ‘difficult sequence’ and is a
consequence of interchain or intrachain association within the
resin matrix (16). In order to circumvent this problem the use of
N-(2-hydroxy 4-methoxybenzyl) derivatives of amino acids has
recently been proposed (11,17). These N-protected amino acids
prevent agregation through inter- or intramolecular hydrogen
bonding (17). Gly53 was chosen to introduce a N,O-bisFmoc
derivative in a second synthesis. As shown in Figure 2B, coupling
and deprotection of this amino acid, as well as the subsequent
sequence Met52–Gly44, proceeded correctly. Nevertheless, the
pattern of a new ‘difficult sequence’ appeared after Gly44, as
shown in Figure 2B. Therefore, the N,O-bisFmoc derivative of
N-(2-hydroxy 4-methoxybenzyl)glycine was used twice, at
Gly53 and Gly44, in a third assay. Figure 2C shows that in this
case the synthesis proceeded correctly until the end. This last
synthesis afforded 705 mg crude peptide, reverse phase HPLC
analysis of which is represented in Figure 3A. This crude product
was purified by HPLC on a Vydac C4 column with CH3CN/H2O
containing 0.1% trifluoroacetic acid as eluent. Finally, 90 mg
(21% yield) peptide HRFX1 were obtained. Purity was checked
by analytical HPLC (Fig. 3B) and correct molecular mass was
verified by electrospray mass spectrometry (Fig. 3C).
NMR experiments
In a preliminary assay, the NMR spectrum of synthetic
hRFX1/DBD was achieved in 20 mM acetate buffer, 0.3 mM
DTT, pH 5.4, H2O/D2O 9:1 at 293 K. A large broadening of the
signals, indicating aggregation, was observed under these conditions
(data not shown). In 30% trifluoroethanol in water, 5 mM DTT,
pH 4, at 293 K (data not shown) the linewidths of the signals were
sharper. Figure 4 shows the NH-NH region of the NOESY
spectrum corresponding to this last sample. A large number of
NH-NH correlations could be observed, indicating the presence
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Figure 4. NH-NH region of a two-dimensional 600 MHz 1H NMR NOESY
spectrum corresponding to a solution of the synthetic hRFX1/DBD in H2O/TFE
7:3, pH 4, 5 mM DTT at 293 K. The multiplicity of NH-NH NOE cross-peaks
are indicative of helical structure.
of several helical regions. However, poor resolution of the signals
in the NOESY/Clean-TOCSY spectra prevents sequence-specific
assignment of the resonances by the chain tracing method. A
more detailed analysis will require the use of 15N/13C enrichment
of the hRFX1/DBD motif.
Gel mobility shift assays
To determine whether the synthetic hRFX1/DBD polypeptide is
biologically functional, i.e. capable of binding specifically to
DNA, we performed gel mobility shift assays (Fig. 5A). A 23 bp
double-stranded oligonucleotide containing an inverted repeat
corresponding to the EF-C/MDBP binding site was used.
Depending on the ratio of protein to DNA in the binding
reactions, two different protein–DNA complexes were formed.
Previous studies (5) have demonstrated that the complex of
greater mobility corresponds to a single hRFX1/DBD monomer
bound to one half-site of the oligonucleotide, while the complex
of slower mobility corresponds to binding of two hRFX1/DBD
molecules to the two symmetrical half-sites of the oligonucleotide.
When 10 ng hRFX1/DBD were incubated with 100 000 c.p.m.
(50 pg) 32P-labeled 23 bp DNA (Fig. 5A) only the 1:2
DNA–protein complex is observed. By adding increasing
amounts of unlabeled 23 bp DNA an equilibrium appears
between the 1:1 and 1:2 DNA–protein complexes, with only the
1:1 complex in the presence of excess DNA (50 ng, 3.3 equiv.).
Interestingly, even in the presence of a slight excess of DNA
(20 ng, 1.3 equiv.) to protein, the 1:2 DNA–protein complex was
still as abundant as the 1:1 complex. This clearly indicates that
binding of the first molecule of hRFX1/DBD to the 23 bp DNA
favors binding of a second one in a cooperative manner.
Further gel shift experiments were performed to determine the
minimum size of the DNA fragment required for binding of a
monomer of hRFX1/DBD. A constant amount of hRFX1/DBD was
incubated with double-stranded oligonucleotides of different sizes,
each containing the same EF-C/MDBP half-site. Oligonucleotides
of 20, 19, 16, 13, 12 and 10 bp were tested. Only the results for
oligonucleotides of 16, 13 and 12 bp are shown in Figure 5B.
Since these oligonucleotides contain only a single half-site, the
Figure 5. (A) Gel mobility shift assays were performed with 10 ng hRFX1/DBD
and 100 000 c.p.m. (50 pg) 23 bp double-stranded oligonucleotide containing a
palindromic binding site as shown in Figure 1B. The labeled probe was diluted
with the quantities of unlabeled 23 bp oligonucleotide indicated above the lanes.
In the left lane (–) no protein was added. Positions of free DNA (F) and
protein–DNA complexes resulting from binding of a monomer (M) or a dimer
(D) of hRFX1/DBD are indicated on the right. (B) Gel mobility shift assays
were performed without (–) or with (+) hRFX1/DBD and double-stranded
oligonucleotides of different lengths (16, 13 and 12 bp) containing a single
half-site. Positions of free DNA (F) and the protein–DNA complex resulting
from binding of an hRFX1/DBD monomer (M) are indicated on the right.
Under the conditions used essentially all of the 16 and 13 bp oligonucleotides
are complexed with hRFX1/DBD, while binding to the 12 bp oligonucleotide
is severely impaired.
monomeric protein–DNA complex is exclusively formed. This
complex forms efficiently on the 16 and 13 bp oligonucleotides.
However, binding is largely abolished when the size of the
oligonucleotide is reduced to 12 bp. The minimal size of
oligonucleotide permitting efficient binding thus appears to be 13 bp.
Surface plasmon resonance experiments
In order to study the structural basis of the affinity and selectivity
of the interaction between DNA and hRFX1 protein, surface
plasmon resonance (SPR) measurements were used (18). The
minimal sequence of DNA duplex able to interact with hRFX1
(5′-CCCCTAGCAACAG-3′/5′-CTGTTGCTAGGGG-3′) was
biotinylated at the 5′-end of the first strand and immobilized onto
streptavidin-coated chips of a BIAcore biosensor apparatus.
Figure 6 shows SPR profiles obtained after introducing various
concentrations of hRFX1 in aqueous buffer. Corresponding SPR
signals, obtained in parallel by testing identical concentrations of
hRFX1 on streptavidin-coated biosensor chips without oligo-
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Figure 6. Determination of the kinetic parameters of the interaction of the DBD
of hRFX1 to the DNA duplex using suface plasmon resonance (SPR). The
response functions (sensorgrams) shown illustrate specific binding and
dissociation profiles obtained after various concentrations of hRFX1 protein
were added to the buffer flowing over a biosensor chip coated with the DNA
duplex (CTGTTGCTAGGGG) immobilized via a streptavividin–biotin system.
The data in these sensorgrams are expressed as corrected response units, since
the contribution by the bulk refractive index (background) has been substracted.
For clarity only the sensorgrams obtained using 80 (bottom), 140, 185, 250,
330, 445 and 600 nM (top) hRFX1 are shown. The association constant (Ka =
3.9 ± 0.3 × 105/M/s), dissociation constant (Kd = 6.0 ± 0.24 × 10–2/s) and the
equilibrium dissociation constant (KD = 153 ± 18 nM) determined by this study
are the average of three independent experiments at 25C in 10 mM HEPES,
pH 7.4, 0.15 M NaCl, 10 mM MgCl2, 0.3 mM DTT, 3 mM EDTA, 0.005% P20
with immobilized amounts of DNA duplex ranging from 120 to 170 RU.
nucleotide dimer (to control for bulk refractive index effects),
have been substracted from these values. Therefore these profiles
reflect the specific association between hRFX1 and the immobilized
double-stranded oligonucleotide.
The association and dissociation rate constants were calculated
for different protein concentrations (185, 250, 330, 445, 600 and
800 nM respectively) using the equations reported in Materials
and Methods. Based on these measurements the data fitted a first
order model well, yielding the kinetic parameters of binding. The
values obtained for the association constant Ka (3.9 ± 0.3 ×
105/M/s), the dissociation constant Kd (6.0 ± 0.24 × 10–2/s) and
the equilibrium dissociation constant KD (153 ± 18 nM) are the
average of three independent experiments (Fig. 6). Furthermore,
when the association equilibrium reached a plateau, the resonance
units were converted to a ratio of peptide bound to double-strand
oligonucleotide using the equation given in Materials and
Methods. The 1:1 stoichiometry observed by gel shift assays was
thus confirmed by SPR experiments (not shown). In addition,
hRFX1/DBD was unable to bind single-stranded biotinylated
oligonucleotide (5′-CCCCTAGCAACAG-3′), immobilized on a
streptavidin-coated sensor chip.
DNA duplex melting temperature
DNA denaturation experiments were performed on the 13mer
duplex 5′-CCCCTAGCAACAG-3′/5′-CTGTTGCTAGGGG-3′.
As shown in Figure 7, this oligonucleotide melts at 36C in 10 mM
HEPES, pH 7.4, 1 mM β-mercaptoethanol. Increased stabilization
of this DNA duplex was observed in the presence of hRFX1/DBD
(Fig. 7). Indeed, its melting temperature was raised to 52C in the
Figure 7. Melting temperature of a 1.5 µM solution of DNA duplex 13mer
(5′-CTGTTGCTAGGGG-3′) in 10 mM HEPES, pH 7.4, 1 mM β-mercapto-
ethanol obtained by UV monitoring at 260 nm with a gradient of temperature
ranging from 6 to 70C at 20C/h. An elevation of 16C in this melting
temperature was obtained by adding 2 µM synthetic hRFX1/DBD to this
solution, indicating increased stability of the DNA duplex.
presence of 2 µM hRFX1/DBD (1.3 equiv.). The weak first
transition around 36C in the presence of protein corresponds to
DNA not complexed with hRFX1/DBD. This data is consistent
with the equilibrium dissociation constant determined by BIAcore,
which indicates that under the conditions used for DNA
denaturation the oligonucleotide would not be totally complexed
with hRFX1/DBD.
DISCUSSION
With the aim of characterizing kinetic and physicochemical
constants of a novel DNA binding motif present in the family of
RFX proteins, solid phase peptide synthesis of a 76mer polypeptide,
hRFX1/DBD, was performed using the Fmoc/tBu strategy. In the
first synthesis difficulties in the deprotection steps and incomplete
couplings were observed from Gly44 to Ser49 (Fig. 2A). This is
a consequence of interchain or intrachain association occurring
within the resin matrix in these so-called ‘difficult sequences’
(16). In order to overcome this problem, N-2-hydroxy 4-methoxy-
benzyl derivatives of glycine (11,17) were used at Gly53 in the
second synthesis, then at both Gly44 and Gly53 in the third
synthesis. This led to disappearance of incomplete couplings and
deprotections, as observed in Figure 2C. The fact that glycine is
present two or three residues before the ‘difficult sequence’ and
that this residue has a high propensity to be involved in β-turns
(19) suggests that intramolecular β-sheet formation could be
responsible for the synthesis problem encountered in our case.
Careful characterization of 76 amino acid synthetic hRFX1/DBD
by HPLC and electrospray mass spectrometry (Fig. 3) indicated
that purity of the compound was >95%. This allowed preliminary
1H NMR experiments to be performed in order to investigate the
secondary structure of this polypeptide in solution. The spectrum
of synthetic hRFX1/DBD in aqueous buffer exhibited broad
signals characteristic of aggregation (data not shown). Nevertheless,
addition of trifluoroethanol (30%) to the aqueous solution (data
not shown) improved resolution of the proton signals leading to
the observation in the NOESY spectrum of a pattern characteristic
of helical structure (Fig. 4). This is in agreement with secondary
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structure predictions previously described for this sequence (see
Fig. 1A) (20).
Gel mobility shift assays were performed with the synthetic
peptide showing that it was able to bind to a double-stranded
23mer oligodeoxynucleotide containing the binding site of native
hRFX1. Due to the presence of inverted repeats in the DNA, the
peptide was shown to form a 2:1 complex in a cooperative manner
with this oligonucleotide, as is observed with entire hRFX1
protein. Using oligonucleotides of different lengths, the optimum
double-stranded oligonucleotide sequence leading to a 1:1
complex with hRFX1/DBD was determined to be the 13mer
sequence 5′-CCCCTAGCAACAG-3′/5′-CTGTTGCTAGGGG-3′
(Fig. 5).
This 5′-biotinylated DNA 13mer was used in SPR experiments
to determine its association (4 × 105/M/s) and dissociation
constants (6 × 10–2/s) for the hRFX1/DBD peptide, leading to an
equilibrium dissociation constant KD of 153 nM. These values are
in agreement with those found for other nucleic acid binding
motifs, such as the zinc finger domain of HIV-1 NCp7 (21).
However, a high selectivity and a higher affinity, by at least three
or four orders of magnitude, of hRFX1 proteins for the
EFC/MDBP binding site are  expected to result from a
cooperative effect between the two subunits of the hRFX1 dimer.
This was observed with several DNA binding proteins, such as
Escherichia coli catabolite activator protein, which binds DNA as
a dimer of two identical protomers and exhibits 2-fold symmetrical
interactions with a 22 bp 2-fold symmetrical DNA site (22). The
equilibrium dissociation constant of catabolite activator protein is
in the subnanomolar range, which is in agreement with the
calculated increase in affinity, as compared with a monomer,
resulting from interaction of a dimer with two symmetrical
binding sites on DNA (23).
Finally, DNA duplex denaturation experiments performed on
the DNA 13mer allowed us to demonstrate significant stabilization
of the DNA duplex in the presence of synthetic hRFX1/DBD
peptide.
In conclusion, this study has allowed us to determine the
minimum double-strand DNA binding site and the binding
constants for this domain. The results of these experiments are
essential for subsequent investigation of the three-dimensional
structure in solution of 13C/15N-labeled hRFX1/DBD by NMR
and of its complex with the 13mer oligonucleotides by X-ray
crystallography. These studies are now in progress.
ACKNOWLEDGEMENTS
We would like to acknowledge Dr J.Paoletti for providing UV
spectrometry facilities and for helpful discussions and E.Barras
for excellent technical assistance. We thank C.Dupuis for her
invaluable help in drafting this manuscript.
REFERENCES
1 Reith,W., Herrero-Sanchez,C., Kobr,M., Silacci,P., Berte,C., Barras,E.,
Fey,S. and Mach,B. (1990) Genes Dev., 4, 1528–1540.
2 Reith,W., Ucla,C., Barras,E., Gaud,A., Durand,B., Herrero-Sanchez,C.,
Kobr,M. and Mach,B. (1994) Mol. Cell. Biol., 14, 1230–1244.
3 Wu,S.-Y. and McLeod,M. (1995) Mol. Cell. Biol., 15, 1479–1488.
4 Emery,P., Durand,B., Mach,B. and Reith,W. (1997) Nucleic Acids Res., 24,
803–807.
5 Siegrist,C.A., Durand,B., Emery,P., David,E., Hearing,P., Mach,B. and
Reith,W. (1993) Mol. Cell. Biol., 13, 6375–6384.
6 Garcia,A.D., Ostaptchuk,P. and Hearing,P. (1993) J. Virol., 67, 3940–3950.
7 Steimle,V., Durand,B., Barras,E., Zufferey,M., Hadam,M.R., Mach,B. and
Reith,W. (1995) Genes Dev., 9, 1021–1032.
8 Kern,I., Steimle,V., Siegrist,C. and Mach,B. (1995) Int. Immunol., 7,
1295–1299.
9 Mach,B., Steimle,V., Martinez-Soria,E. and Reith,W. (1996) Annu. Rev.
Immunol., 14, 301–331.
10 Merrifield,R.B. (1963) J. Am. Chem. Soc., 85, 2149–2152.
11 Johnson,T., Quibell,M. and Sheppard,R.C. (1995) J. Peptide Sci., 1, 11–25.
12 Griesinger,C., Otting,G., Wüthrich,K. and Ernst,R.R. (1988) J. Am. Chem.
Soc., 110, 7870–7872.
13 Jeener,J., Meier,B.H., Bachmann,P. and Ernst,R.R. (1982) J. Chem. Phys.,
71, 4546–4553.
14 Marion,D. and Wüthrich,K. (1983) Biochem. Biophys. Res. Commun., 113,
967–974.
15 Atherton,E., Logan,C.J. and Sheppard,R.C. (1981) J. Chem. Soc. Perkin
Trans., 1, 538.
16 Larsen,B.D. and Holm,A.(1994) Int. J. Peptide Protein Res., 43, 1–9.
17 Hyde,C., Johnson,T., Owen,D., Quibell,M. and Sheppard,R.C. (1994)
In Epton,R. (ed.), Innovation and Perspectives in Solid Phase
Synthesis—Peptides, Proteins and Nucleic Acids. Mayflower Worldwide,
Birmingham, AL, Vol. 3, pp. 29–38.
18 O’Shannessy,D.J., Brigham,B.M., Soneson,K.K., Hensley,P. and Brooks,J.
(1993) Anal. Biochem., 212, 457–468.
19 Hutchinson,E.G. and Thornton,J.M. (1994) Protein Sci., 3, 2207–2216.
20 Emery,P., Strubin,M., Hofman,K., Bucher,P., Mach,B. and Reith,W. (1995)
Mol. Cell. Biol., 16, 4486–4494.
21 Mély,Y., de Rocquigny,H., Sornas-Jimeno,M., Keith,G., Roques,B.P.,
Marquet,R. and Gérard,D. (1995) J. Biol. Chem. 270, 1650–1656.
22 Parkinson,G., Gunasekera,A., Vojtechovsky,J., Zhang,X., Kunkel,T.A.,
Berman,H. and Ebright,R.H. (1996) Nature Struct. Biol., 3, 837–841.
23 Le Pecq,J.B., Le Bret,M., Barret,J. and Roques,B.P. (1975) Proc. Natl.
Acad. Sci. USA, 72, 2915–2919.
